ONMI BV

Their core work

ONMI BV is a Dutch private company specializing in the translation of biomedical and nutritional science into consumer-facing products and business applications. Their work sits at the intersection of omics sciences, personalized nutrition, and digital health — contributing commercial and market expertise to research consortia rather than conducting laboratory science themselves. In the PREVENTOMICS project, they contributed knowledge around business models, consumer behavior, and the commercialization of personalized meal recommendations derived from metabolomics data. In Do CHANGE, they worked within a digital cardiac health ecosystem, suggesting a consistent focus on turning complex health data into actionable, user-facing tools.

What they specialise in

How they've shifted over time

ONMI's first H2020 involvement (Do CHANGE, 2015–2018) was in cardiac digital health, with no recorded keywords — suggesting a supporting or enabling role whose precise contribution is not well documented in the CORDIS data. Their second project (PREVENTOMICS, 2018–2022) reveals a sharper profile: they were active in omics, metabolomics, biomarkers, decision support systems, personalized meals, and consumer behavioral change. The shift points toward a deliberate move from general digital health into precision nutrition — a commercially hotter space — with an increasingly explicit focus on connecting scientific outputs to end-user products and business models.

ONMI appears to be positioning itself at the commercial frontier of precision nutrition — where metabolomics data becomes actionable dietary guidance — making them a relevant partner for consortia needing market translation, consumer engagement strategy, or business model development in health-food convergence projects.

How they like to work

ONMI has participated in all H2020 projects as a consortium partner, never as coordinator, which suggests they enter projects to contribute a specific commercial or market-facing capability rather than to drive research agendas. With 31 unique partners across 9 countries over just two projects, they operate in large, diverse consortia — typical of Innovation Actions and Research & Innovation Actions with broad European footprints. There is no evidence of repeated partnerships with the same organizations, suggesting they are comfortable working across varied networks rather than relying on a fixed inner circle.

ONMI has built a network of 31 unique partners across 9 countries through only two projects — an unusually wide reach for such a small portfolio, reflecting the large international consortia typical of H2020 Health and Food calls. Their geographic footprint spans multiple European countries, though no specific regional concentration is visible from the available data.

What sets them apart

ONMI's distinctive value in a research consortium is commercial and consumer-side expertise — they bring business model thinking and behavioral science to projects dominated by laboratory and clinical researchers. This is a genuine gap in most health and food research consortia, where translating scientific findings into viable products and consumer adoption strategies is often underdeveloped. For a coordinator building a precision nutrition or digital health project that needs to demonstrate real-world uptake and market viability, ONMI offers a differentiated contribution that pure research institutions cannot provide.

Highlights from their portfolio

• PREVENTOMICS
  The largest thematic stretch in ONMI's portfolio — linking omics laboratory science to consumer dietary behavior and business models — and the project where their keyword-rich contribution is most clearly documented.
• Do CHANGE
  ONMI's highest-funded project (EUR 674,688) and their entry into H2020, covering cardiac digital health at a time when such ecosystems were early-stage and commercially uncertain.